The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
The company is focused on the development of novel treatments for RNA viruses
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
The company has has 10 existing labs in India
The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio
The collaboration aims to deliver greater insights to the oncology fraternity, predict patient therapy responses and enable therapy selection resulting in optimal treatment outcomes.
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
The new products include the COAG Line automated, semi-automated and POC systems manufactured by Diagon Hungary
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Subscribe To Our Newsletter & Stay Updated
